fbpx

Pablo Zuanic On Trade To Black To Talk Cannabis Reports

Welcome back to the Trade To Black Podcast! In today’s live streamed episode, we’ll be talking about some cannabis and psychedelic news, including what’s happening in the states of Michigan and New Jersey. We’ll also have a special interview with Pablo Zuanic, a seasoned equity analyst renowned for his expertise in both the cannabis and psychedelics sectors, one of the most well known and respected names in the space, and he’ll be giving us some market insights.

Millennial investor Anthony Varrell and host Shadd Dales kick off with Into The Wire. First up, news out of the state of Michigan with figures on rec use. Michigan managed to crack $3bn for the year 2023. Spread over the population of the state, that’s a little more than $300 for every person who lives there. You can bet that brands are taking notice of that huge opportunity, because it has eclipsed the performance of a lot of other, larger markets.

The second big headline is interesting news from the lawmakers in New Jersey. There’s legislation to allow for treatment centers and the manufacture of psilocybin-based therapies. It was written in 2023, revised, and looks like it might now pass. Get the scoop right here.

In our interview portion, Pablo’s firm, Zuanic & Associates, has been at the forefront of producing cutting-edge reports that provide invaluable insights into the industry. We’ll explore the latest reports recently released by Pablo’s firm which cover developments in the cannabis market. We’ll also chat about some of the many influential factors that are shaping the industry’s future.

Discover the unique perspectives and expert insights that Pablo Zuanic brings to the world of financial consulting, research, and advisory projects when you join us for this enlightening conversation about the cannabis market. Pablo Zuanic is one of the industry’s leading experts; you won’t want to miss out.


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More